SEC Filing Summary: Second Sight Medical Products, Inc.
Business Context and Reporting Period
This Form 8-K was filed on July 17, 2017, by Second Sight Medical Products, Inc. (Note: The request metadata referenced "Vivani Medical, Inc.", but the filing text identifies the registrant as Second Sight Medical Products, Inc.). The report discloses a material event regarding the company's regulatory progress for its Orion Cortical Visual Prosthesis System.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and contains no financial statements or performance data.
Material Changes
On July 17, 2017, the Company submitted an application for an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA). This application seeks approval to conduct an early feasibility study of the Orion Cortical Visual Prosthesis System involving a clinical trial of up to five patients.
Guidance, Outlook, and Risks
- Regulatory Process: The Company notes that IDE applications typically involve several rounds of question and answer interactions with the FDA.
- Timing Uncertainty: The timing of the FDA review and approval process is described as unpredictable.
- No Assurance: The filing explicitly states that no assurance can be given as to when the Company will receive the IDE for the planned Orion feasibility study.
Investor Verification Checklist
- Confirm the current status of the IDE application with the FDA.
- Monitor for any FDA questions or requests for additional information regarding the Orion system.
- Verify the timeline for the commencement of the early feasibility study, if approved.
- Review subsequent filings for updates on the clinical trial enrollment of up to five patients.